Business

Combative U.S. FDA panel votes towards Biogen Alzheimer's drug

Combative U.S. FDA panel votes against Biogen Alzheimer's drugThe FDA still could decide to approve the drug, aducanumab, making it the first new Alzheimer’s treatment in decades. Several of the 11 panel members expressed resentment that the FDA’s early view of aducanumab – which was made public on Wednesday – was biased toward a favorable outcome for Biogen.

Read More: https://www.kbcchannel.tv | For More Business Articles | Visit Our Facebook & Twitter @kbcchanneltv | Making The Invisible, Visible


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker
%d bloggers like this: